IRAK signalling in cancer

British Journal of Cancer

Volumn 112, Issue 2, 2015, Pages 232-237

  Rhyasen, G W ^a,b,c   Starczynowski, D T ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Cancer; IRAK; Leukaemia; Myelodysplasia; NF B

Indexed keywords

BENZIMIDAZOLE PYRIDINE; GINSENOSIDE RB 1; IBRUTINIB; IMIDAZO[1,2 A]PYRIDINO PYRIDINE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; N ACYL 2 AMINOBENZIMIDAZOLE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; BURKITT LYMPHOMA; CHRONIC MYELOID LEUKEMIA; DRUG SYNTHESIS; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; MELANOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; SUMOYLATION; UBIQUITINATION; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84922337316     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.513     Document Type: Short Survey

References (43)

1. Akinleye A, Furqan M, Adekunle O (2013) Ibrutinib and indolent B-cell lymphomas. Clin Lymphoma Myeloma Leuk 14: 253-260.
2. Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, Juliusson G, Richter J, Jaras M, Fioretos T (2013) Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121: 3709-3713.
3. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U (2012) Overexpression of Il-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120: 1290-1298.
4. Buckley GM, Ceska TA, Fraser JL, Gowers L, Groom CR, Higueruelo AP, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V (2008a) Irak-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-A]pyridine binding. Bioorg Med Chem Lett 18: 3291-3295.
5. Buckley GM, Fosbeary R, Fraser JL, Gowers L, Higueruelo AP, James LA, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V (2008b) Irak-4 inhibitors. Part III: A series of imidazo[1,2-A]pyridines. Bioorg Med Chem Lett 18: 3656-3660.
6. Buckley GM, Gowers L, Higueruelo AP, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V, Fraser JL (2008c) Irak-4 inhibitors. Part 1: a series of amides. Bioorg Med Chem Lett 18: 3211-3214.
7. Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, Abutbul S, Huszar M, Dinarello CA, Apte RN, Voronov E (2013) The role of Il-1beta in the early tumor cell-induced angiogenic response. J Immunol 190: 3500-3509.
8. Chaudhary D, Robinson S, Masse CE, Wessel MD, Watts S, Greenwood J, Shelley M, Brewer M, Harriman G, Frye LL, Wester RT, Kapeller R, Romero D (2012) Identification of highly potent and selective interleukin-1 receptor- associated kinase 4 inhibitors for the treatment of rheumatic diseases. [abstract]. Arthritis Rheum 64(Suppl 10): 1062.
9. Chaudhary D, Romero Dl WN, Greenwood Jr Robinson S, Shelley M, Morin M, Kapeller R, Westlin WF (2013) Synergistic blockade of activated B-cell-like DLBCL proliferation with a selective inhibitor of IRAK4 in combination with inhibition of the B-cell receptor signaling network [abstract]. Blood 122.
10. Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD (2008) Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptorand toll-like receptor-mediated Nf-KappaB activation. Mol Cell Biol 28: 3538-3547.
11. Day N, Tangsinmankong N, Ochs H, Rucker R, Picard C, Casanova JL, Haraguchi S, Good R (2004) Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J Pediatr 144: 524-526.
12. del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P, Escoll P, Baos R, Caveda L, Garcia F, Arnalich F, Lopez-Collazo E (2005) Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 174: 3032-3040.
13. Eckfeldt CE, Mendenhall EM, Flynn CM, Wang TF, Pickart MA, Grindle SM, Ekker SC, Verfaillie CM (2005) Functional analysis of human hematopoietic stem cell gene expression using zebrafish. Plos Biol 3: E254.
14. Ferreri AJ, Ernberg I, Copie-Bergman C (2009) Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med 265: 421-438.
15. Huang Y, Li T, Sane DC, Li L (2004) Irak1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem 279: 51697-51703.
16. Joh EH, Lee IA, Jung IH, Kim DH (2011) Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation-the key step of inflammation. Biochem Pharmacol 82: 278-286.
17. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S (2008) Sequential control of toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 9: 684-691.
18. Kobayashi K, Hernandez LD, Galan JE, Janeway Jr CA, Medzhitov R, Flavell RA (2002) IRAK-M is a negative regulator of toll-like receptor signaling. Cell 110: 191-202.
19. Kollewe C, Mackensen AC, Neumann D, Knop J, Cao P, Li S, Wesche H, Martin MU (2004) Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem 279: 5227-5236.
20. Koziczak-Holbro M, Gluck A, Tschopp C, Mathison JC, Gram H (2008) IRAK-4 kinase activity-dependent and -independent regulation of lipopolysaccharide-inducible genes. Eur J Immunol 38: 788-796.
21. Lin SC, Lo YC, Wu H (2010) Helical assembly in the Myd88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885-890.
22. Maschera B, Ray K, Burns K, Volpe F (1999) Overexpression of an enzymically inactive interleukin-1-receptor-associated kinase activates nuclear factor-kappaB. Biochem J 339(Pt 2): 227-231.
23. Medvedev AE, Thomas K, Awomoyi A, Kuhns DB, Gallin JI, Li X, Vogel SN (2005) Cutting edge: expression of IL-1 receptor-associated kinase-4 (IRAK-4) proteins with mutations identified in a patient with recurrent bacterial infections alters normal IRAK-4 interaction with components of the IL-1 receptor complex. J Immunol 174: 6587-6591.
24. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM (2011) Oncogenically active Myd88 mutations in human lymphoma. Nature 470: 115-119.
25. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208.
26. Pauls E, Nanda SK, Smith H, Toth R, Arthur JS, Cohen P (2013) Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice. J Immunol 191: 2717-2730.
27. Powers JP, Li S, Jaen JC, Liu J, Walker NP, Wang Z, Wesche H (2006) Discovery and initial sar of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett 16: 2842-2845.
28. Qin J, Jiang Z, Qian Y, Casanova JL, Li X (2004) IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness. J Biol Chem 279: 26748-26753.
29. Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT (2013) Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24: 90-104.
30. Robinson DD, Sherman W, Farid R (2010) Understanding kinase selectivity through energetic analysis of binding site waters. ChemMedChem 5: 618-627.
31. Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, Mckenna C, Bansal N, Ochoa A, Davila E (2012) Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res 72: 6209-6216.
32. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A (2010) Identification of mir-145 and mir-146a as mediators of the 5q- syndrome phenotype. Nat Med 16: 49-58.
33. Su J, Richter K, Zhang C, Gu Q, Li L (2007) Differential regulation of interleukin-1 receptor associated kinase 1 (IRAK1) splice variants. Mol Immunol 44: 900-905.
34. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC (2002) Severe impairment of interleukin-1 and toll-like receptor signalling in mice lacking IRAK-4. Nature 416: 750-756.
35. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M (2010) Tobacco smoke promotes lung tumorigenesis by triggering Ikkbeta- and JNK1-dependent inflammation. Cancer Cell 17: 89-97.
36. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR (2012) Myd88 L265p somatic mutation in Waldenstrom's Macroglobulinemia. N Engl J Med 367: 826-833.
37. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, Dinarello CA (2000) IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 97: 734-739.
38. Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP (2006) Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure 14: 1835-1844.
39. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G (2013) Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27: 1832-1840.
40. Xie Q, Gan L, Wang J, Wilson I, Li L (2007) Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 44: 3453-3461.
41. Yamin TT, Miller DK (1997) The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation. J Biol Chem 272: 21540-21547.
42. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP (2013) A mutation in Myd88 (L265p) supports the survival of lymphoplasmacytic cells by activation of bruton tyrosine kinase in Waldenstrom Macroglobulinemia. Blood 122: 1222-1232.
43. Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, Lograsso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR, Gray NS (2012) Discovery of potent and selective covalent inhibitors of JNK. Chem Biol 19: 140-154.